The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2016 | The benefits of lenalidomide and dexamethasone for multiple myeloma
Katja Weisel, MD from University Hospital Tuebingen, Tuebingen, Germany discusses the slowly progressing myeloma and outlines how there are clear benefits to receiving lenalidomide and dexamethasone based backbone therapy for patients who have not had success with a proteasome inhibitor based first-line of treatment. Patients receiving this treatment show a sustained and durable responses with a progression-free survival (PFS) of 15-19 months. Dr Weisel continues to discuss the potential of combining lenalidomide and dexamethasone with a combination treatment. For instance carfilzomib, lenalidomide and dexamethasone combinations (NCT01080391). Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
